Stephen Liu: Novel epigenomic cfDNA approach in diagnosis of EGFR mutant NSCLC
Stephen Liu shared a post on X about a recent paper by Jacob E. Berchuck et al. published in AACR Journals, commenting:
“SCLC transformation in EGFR mutant NSCLC likely underdiagnosed – requires tissue biopsy but can liquid biopsy help? Novel epigenomic cfDNA approach in Clinical Cancer Research shows uses histone modification to distinguish histologies. Very promising approach!”
Authors: Talal El Zarif, Catherine B. Meador, Xintao Qiu, Ji-Heui Seo, Matthew P. Davidsohn, Hunter Savignano, Gitanjali Lakshminarayanan, Heather M. McClure, John Canniff, Brad Fortunato, Rong Li, Mandeep K. Banwait, Karl Semaan, Marc Eid, Henry Long, Yin P. Hung, Navin R. Mahadevan, David A. Barbie, Matthew G. Oser, Zofia Piotrowska, Toni K. Choueiri, Sylvan C. Baca, Aaron N. Hata, Matthew L. Freedman, Jacob E. Berchuck.
Source: Stephen Liu/X
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.